Peer-reviewed veterinary case report
Outcomes and factors in 107 dogs with aggressive T-cell lymphoma
By Purzycka, Katarzyna et al.·Published in Veterinary and comparative oncology·2020·Queen Mother Hospital for Animals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
- Species:
- dog
Plain-English summary
A group of dogs, mostly Labradors, Boxers, and mixed breeds, were diagnosed with a serious type of cancer called multicentric non-indolent T-cell lymphoma. Many of these dogs showed symptoms like swollen lymph nodes and had varying responses to treatment. About 80% responded well to initial therapy, especially those treated with a specific drug called procarbazine. However, the average time before the cancer progressed was about 105 days, and the overall survival time was around 136 days. This type of lymphoma is aggressive, and certain factors like blood cell counts can help predict how well a dog might respond to treatment.
People also search for: dog lymphoma treatment · T-cell lymphoma in dogs · prognosis for dog cancer · symptoms of lymphoma in dogs · canine cancer survival rates
Abstract
Canine lymphoma, as the most common haematopoietic malignancy, encompasses a group of heterogeneous diseases and even within the T-cell immunophenotype, differences in clinical presentation and responses to treatment exist. The aim of this retrospective study was to determine outcomes and prognostic factors of 107 dogs with multicentric non-indolent T-cell lymphoma (TCL) receiving lomustine-based (70%) and non-lomustine-based (30%) treatment. The majority were Labradors, Boxers, mixed-breed dogs and Dogue de Bordeaux. Eighty-six percent were substage b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement and 12% had other extra-nodal sites of disease. The overall response rate to induction therapy was 80%; dogs receiving procarbazine in the induction protocol (P = .042), dogs with neutrophil concentration below 8.7 × 10e/L (P = .006) and mitotic rate below 10 per 5 high power field (P = .013), had greater response rates. Median progression-free survival (PFS) for the first remission was 105 days; lack of expression of CD3 on flow cytometry (P < .0001) and pretreatment with steroid (P = .012) were significantly associated with shorter PFS. Median overall survival time (OST) was 136 days; co-expression of CD79a (P = .002), lack of CD3 expression on flow cytometry, presence of anaemia (P = .007), and monocytopenia (P = .002) were predictive of shorter OST. Multicentric non-indolent TCL in dogs is an aggressive cancer with new possible prognostic factors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32163214/